Senores Pharmaceuticals LimitedQ2 FY27 Results & Financial Update
Senores Pharmaceuticals Limited: Q2 FY27 consolidated results and company financials – revenue ₹192.33 Cr, PAT ₹36.60 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Senores Pharmaceuticals price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Senores Pharmaceuticals Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Senores Pharmaceuticals reported a consolidated revenue from operations of INR 192.33 crore for the quarter ended September 30, 2026 (Q2 FY27), representing a sequential growth of 6.73% compared to INR 180.21 crore in Q1 FY27. Total income for the quarter stood at INR 201.27 crore, advancing from INR 183.02 crore in the preceding quarter.
Profitability demonstrated strong sequential expansion. Profit Before Tax (PBT) reached INR 47.58 crore in Q2 FY27, marking a 20.58% increase over INR 39.46 crore in Q1 FY27. Profit After Tax (PAT) for the quarter grew by 20.20% sequentially to INR 36.60 crore from INR 30.45 crore, leading to an improved PAT margin of 19.03% compared to 16.90% in the previous quarter.
Basic Earnings Per Share (EPS) for Q2 FY27 rose to INR 8.85 from INR 6.61 reported in Q1 FY27, reflecting a sequential gain of 33.89%. The quarter's bottom-line performance was supported by robust operational delivery and higher other income, which stood at INR 8.94 crore compared to INR 2.81 crore in Q1 FY27.
On a year-over-year basis, the investor presentation highlights a 25% revenue growth and a 38.4% EBITDA growth for Q2 FY27 compared to Q2 FY26, driven by strong performance in regulated markets and ongoing portfolio commercialization. Management noted that EBITDA growth was achieved despite continuous investments in subsidiaries such as Apnar, Zoraya, and Amerisyn.
Operational momentum during the quarter included the commercialization of 3 new product strengths under existing ANDAs in the regulated markets, including 2 strengths sold in the US for the first time by any company. The company also received approval for 1 ANDA and 3 sANDAs during Q2 FY27.
The balance sheet reflects active deployment of capital, with total shareholder funds standing at INR 1,002.9 crore as of September 30, 2026. Non-current borrowings were INR 212.9 crore, while current borrowings stood at INR 181.6 crore. Out of the INR 500 crore IPO proceeds, INR 418.83 crore had been utilized by the end of September 2026, leaving INR 81.17 crore parked in bank fixed deposits and current accounts for earmarked subsidiary capex and acquisitions.
01 · Business model
What does Senores Pharmaceuticals do?
Senores Pharmaceuticals Limited is a research-driven, formulation-focused global pharmaceutical company engaged in the development, manufacturing, and commercialization of specialized and complex pharmaceutical products. Its core portfolio spans various therapeutic areas including oral solids, oral liquids, injectables, and active pharmaceutical ingredients (APIs).
The company serves both regulated markets—predominantly the United States, Canada, and the United Kingdom—and emerging and mid-tier markets across 40+ countries. In regulated markets, it operates through a model of long-term marketing and distribution arrangements, strategic joint ventures, and contract development and manufacturing (CDMO/CMO) services tailored for specialty, government, and controlled substance supplies.
Senores operates accredited manufacturing facilities across the United States and India. Its footprint includes a USFDA-approved formulation plant in Atlanta, US, formulation and API plants in Gujarat, India, and specialized subsidiaries such as Aavis Pharmaceuticals, Apnar Pharma, Ratnatris Pharmaceuticals, Zoraya Pharmaceuticals, and Amerisyn LLC.
The business model integrates upstream R&D capabilities—with a dedicated team of over 100 professionals—with forward integration into direct marketing, B2C channels, and institutional government procurement contracts to capture higher value across the pharmaceutical value chain.
02 · Historical context
What shaped the business before this quarter
Incorporated as Senores Pharmaceuticals Pvt. Ltd. in India in 2017 before expanding its operational footprint globally.
Entered the active pharmaceutical ingredient segment in 2021 through the acquisition of Ratnagene Lifescience Pvt. Ltd., which was subsequently merged into the company.
Acquired a majority stake in Havix in 2023 to enhance manufacturing capabilities for regulated markets through its USFDA-approved facility in Atlanta.
Expanded presence in emerging markets in 2023 by acquiring shares in Ratnatris Pharmaceuticals Pvt. Ltd.
Completed a successful initial public offering and listed on BSE and NSE in 2024.
Acquired a 75% stake in Apnar Pharma and a 51% stake in Zoraya Pharmaceuticals in late 2025, followed by the establishment of Amerisyn LLC in 2026 for US federal and defense sector supply.
03 · Financial snapshot
Current quarter vs the available comparable
| Metric | Q2 FY27 | Previous quarter |
|---|---|---|
| Revenue from operations | ₹192.33 Cr | ₹180.21 Cr |
| Total income | ₹201.27 Cr | ₹183.02 Cr |
| Profit before tax | ₹47.58 Cr | ₹39.46 Cr |
| Profit after tax | ₹36.60 Cr | ₹30.45 Cr |
| EPS | ₹8.85 | ₹6.61 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Regulated markets (US, Canada, UK) remain the primary revenue engine, contributing 71% of total revenue in H1 FY27 with segment revenue growing 27.9% year-over-year to INR 136.7 crore in Q2 FY27.
Emerging markets contributed 20% of H1 FY27 revenue, registering a 21.2% year-over-year revenue increase to INR 38.4 crore in Q2 FY27, backed by 558 product registrations across more than 40 countries.
Expansion in CDMO/CMO commercialized products—growing from 16 to 19 products in regulated markets—provided steady and predictable cash flows through early-stage drug development collaborations.
What drove margins
Consolidated gross margin expanded by 250 bps year-over-year to 65.4% in Q2 FY27, supported by a favorable product mix weighted toward complex specialty formulations and regulated market products.
EBITDA margin reached 30.0% in Q2 FY27 (up 290 bps year-over-year from 27.1%), even as the company absorbed initial operating costs and investments in newer subsidiaries such as Apnar, Zoraya, and Amerisyn.
Ongoing R&D expenditures stood at approximately 11% of revenue in H1 FY27, supporting a pipeline of complex molecules, controlled substances, and differentiated dosage forms.
05 · Demand, customers & order book
Where demand is coming from
The company holds 64 approved ANDAs representing 207 strengths, with 23 commercialized ANDAs spanning 54 strengths, and 41 ANDAs pending launch.
CDMO pipeline products in regulated markets expanded to 34 products representing 108 strengths, up from 13 products and 45 strengths in Q2 FY26.
Branded generics business serves over 200 hospitals in India, including key healthcare partners such as AllMS, Apollo Hospitals, SAL Hospital, PGI, and Tata Medical Center.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Reported Q2 FY27 revenue of INR 136.7 crore (up 27.9% YoY). H1 FY27 segment EBITDA margin stood at approximately 42%, underpinned by 64 approved ANDAs and 207 associated strengths.
Reported Q2 FY27 revenue of INR 38.4 crore (up 21.2% YoY). H1 FY27 segment EBITDA margin stood at approximately 9%, driven by a portfolio of 558 approved products and 944 product applications filed.
Reported Q2 FY27 revenue of INR 9.5 crore (down 20.5% YoY), supplying critical care injectables to over 200 hospitals across India through a field team of over 100 employees.
Reported Q2 FY27 revenue of INR 7.8 crore, marking a 126.2% year-over-year increase from INR 3.4 crore in Q2 FY26.
Geography and market mix
Strengthened US market presence through subsidiary Amerisyn LLC for federal and defense sector procurements, and Zoraya Pharmaceuticals as a B2C commercial anchor.
Maintained active marketing across 40+ countries, with key emerging markets including the Philippines, Peru, Ghana, Nigeria, Myanmar, Guatemala, and Kenya.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The USFDA-approved facility in Atlanta, US, features 3 manufacturing lines across 185,300 sq. ft. with an annual installed oral solid dosage capacity of 1.5 billion units.
The Ahmedabad/Chhatral facility houses 12 manufacturing lines across 378,943 sq. ft., providing annual installed capacities of 1,397.96 million units for general oral dosage, 49.92 million units for injectables, and 511.68 million units for beta-lactam orals.
Apnar Pharma plant operates capacities of 275 million tablets, 225 million capsules, and 16 million bottles annually, with expansion potential up to 600 million tablets, 500 million capsules, and 32 million bottles.
API Units I and II in Gujarat maintain annual installed capacities of 25 MT and 144 MT respectively, supporting 17 commercialized APIs.
Projects, capex and execution
As of September 30, 2026, out of earmarked IPO funds, INR 6.98 crore out of INR 41.98 crore had been utilized for setting up a sterile injection facility at the Atlanta plant (Havix), INR 1.69 crore out of INR 25 crore for Apnar facility expansion in Vadodara, and INR 7.14 crore out of INR 24.63 crore for OSD manufacturing expansion in Atlanta.
08 · Strategy & new businesses
How the company is trying to change its growth mix
Strategic joint venture Amerisyn LLC provides direct access to high-barrier US federal and defense sector pharmaceutical procurements, including Department of Veteran Affairs and Department of Defense contracts.
Zoraya Pharmaceuticals serves as the US B2C commercial anchor and forward integration arm, leveraging 15 years of direct marketing experience to accelerate product distribution.
09 · Reported developments
What changed operationally
Commercialized 3 new strengths in Q2 FY27 under existing ANDAs, including 2 strengths sold in the US for the first time by any company.
Received approval for 1 ANDA and 3 sANDAs during Q2 FY27 across regulated market operations.
10 · Items worth noticing
The line items that can distort a quick read
Other income increased to INR 8.94 crore in Q2 FY27 from INR 2.81 crore in Q1 FY27.
Tax expense for Q2 FY27 was recorded at INR 10.98 crore, compared to INR 9.01 crore in Q1 FY27.
11 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Net cash flow from operating activities for H1 FY27 stood at INR 29.2 crore, compared to INR 24.2 crore in H1 FY26, after accounting for working capital changes of negative INR 84.7 crore.
Cash and cash equivalents stood at INR 18.0 crore as of September 30, 2026, alongside other bank balances of INR 82.7 crore.
Capital allocation & funding
Non-current borrowings stood at INR 212.9 crore and current borrowings at INR 181.6 crore as of September 30, 2026, compared to INR 194.9 crore and INR 132.2 crore respectively as of March 31, 2026.
Finance costs for Q2 FY27 were reported at INR 8.77 crore, compared to INR 7.17 crore in Q1 FY27.
12 · Management guidance & targets
What management is targeting from here
Management stated that H2 FY27 is expected to be considerably better than H1 owing to anticipated product launches, ongoing revenue ramp-ups from Zoraya and Amerisyn, and commercialization of 13 ANDAs with 41 strengths in government channels.
13 · Beyond the numbers
What changed beyond the numbers
Reported update
Great Place to Work Certification
Senores Pharmaceuticals received the 'Great Place to Work' certification for the period May 2026 to May 2027.
14 · Previous-quarter changes
What changed since the previous quarter
Revenue grew by 6.73% sequentially from INR 180.21 crore in Q1 FY27 to INR 192.33 crore in Q2 FY27, while PAT expanded by 20.20% to INR 36.60 crore.
15 · Key Q&A
The quarter, answered directly
What does Senores Pharmaceuticals do?
Senores Pharmaceuticals Limited is a research-driven, formulation-focused global pharmaceutical company engaged in the development, manufacturing, and commercialization of specialized and complex pharmaceutical products. Its core portfolio spans various therapeutic areas including oral solids, oral liquids, injectables, and active pharmaceutical ingredients (APIs).
What is the clearest takeaway from Q2 FY27?
Senores Pharmaceuticals reported a consolidated revenue from operations of INR 192.33 crore for the quarter ended September 30, 2026 (Q2 FY27), representing a sequential growth of 6.73% compared to INR 180.21 crore in Q1 FY27. Total income for the quarter stood at INR 201.27 crore, advancing from INR 183.02 crore in the preceding quarter.
What drove revenue or demand?
Regulated markets (US, Canada, UK) remain the primary revenue engine, contributing 71% of total revenue in H1 FY27 with segment revenue growing 27.9% year-over-year to INR 136.7 crore in Q2 FY27.
What mattered most for margins or profitability?
Consolidated gross margin expanded by 250 bps year-over-year to 65.4% in Q2 FY27, supported by a favorable product mix weighted toward complex specialty formulations and regulated market products.
What changed operationally beyond the headline numbers?
The USFDA-approved facility in Atlanta, US, features 3 manufacturing lines across 185,300 sq. ft. with an annual installed oral solid dosage capacity of 1.5 billion units.
What is management guiding or targeting from here?
Management stated that H2 FY27 is expected to be considerably better than H1 owing to anticipated product launches, ongoing revenue ramp-ups from Zoraya and Amerisyn, and commercialization of 13 ANDAs with 41 strengths in government channels.
16 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
17 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
H2 FY27 Product Launches: Execution of anticipated new product launches and government channel commercializations slated for H2 FY27.
- 02
Capex Deployment: Progress on unutilized IPO proceeds of INR 81.17 crore dedicated to facility expansions at Atlanta (Havix) and Vadodara (Apnar).
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.